top of page

MedChem Pipeline

Our laboratory, from time to time, negotiates with industry to advance lead compounds into preclinical or advanced late stage models. If you are in industry and are interested in technology transfer from the Njoo lab, email edward.njoo@asdrp.org. 

​

Technology Transfers must be performed in accordance to ASDRP's policies on patenting and publishing student-derived research, and are jointly negotiated by our legal team and the legal team of an industrial collaborator.

Reverse Logic Linkers for Self-Regulating Drug Delivery

Collaboration with: ReThink64 Bionetworks PBC, Stanford University

Currently: US Patent filed in January 2024 (collaboration with industry and with Yamamoto lab), advanced organoid studies underway.

Prodrugs of Bufadienolide Natural Products for Selective Breast Cancer Targeting

Collaboration with: SunnyBay Biotech Co.

Currently: Preclinical (in vivo) models

Antibody-Drug Conjugates with Engineered Topoisomerase Inhibitors

Collaboration with: SunnyBay Biotech Co.

Currently: Preclinical (in vivo) models

bottom of page